疏肝胃安颗粒联合埃索美拉唑镁肠溶片和莫沙必利片治疗胃食管反流病56例临床观察  

Clinical Observation on Shugan Weian Granules(疏肝胃安颗粒) Combined with Esomeprazole and Mosapride in the Treatment of 56 Cases of Gastroesophageal Reflux Disease

作　　者：周英武[1] 张玉禄 ZHOU Yingwu;ZHANG Yulu(Beijing Gulou Traditional Chinese Medicine Hospital,Beijing,100007;The Third Affiliated Hospital of Beijing University ofChinese Medicine)

机构地区：[1]北京市鼓楼中医医院,100007 [2]北京中医药大学第三附属医院

出　　处：《中医杂志》2019年第13期1118-1122,共5页Journal of Traditional Chinese Medicine

基　　金：北京中医药科技发展资金(JJ2018-18)

摘　　要：目的评价疏肝胃安颗粒联合埃索美拉唑镁肠溶片和莫沙必利片治疗胃食管反流病的临床疗效。方法 120例胃食管反流病患者随机分为对照组和治疗组各60例,对照组给予埃索美拉唑镁肠溶片(20 mg/次,每日2次)和莫沙必利片(5 mg/次,每日3次)治疗,治疗组在对照组的基础上给予疏肝胃安颗粒治疗,每日1剂,两组疗程均为8周。治疗前后两组患者分别进行反流性疾病问卷(RDQ)、SF-36生活质量量表评分、24 h食管pH监测,治疗后根据治疗前后电子胃镜分级评分变化情况统计两组胃镜疗效。结果两组治疗后反酸、反流、烧心和非心源性胸痛症状评分和RDQ总分均较治疗前显著减少(P<0.01),而治疗组RDQ总分和各症状评分较对照组降低更显著(P<0.05或P<0.01)。治疗组SF-36生活质量评分所有维度和对照组除了情感职能和精神健康外的其他维度评分均较治疗前明显升高(P<0.05或P<0.01),且治疗组对生理功能、躯体疼痛、总体健康、情感职能、精神健康维度方面的改善作用明显优于对照组(P<0.05或P<0.01)。两组患者的反流持续≥5 min次数、最长反流持续时间、pH<4总时间百分比、DeMeester得分均较治疗前有显著下降(P<0.05或P<0.01),且治疗组患者的最长反流持续时间和DeMeester得分较对照组降低更显著(P<0.05)。对照组胃镜疗效总有效率77.19%,治疗组为85.71%,两组比较差异无统计学意义(P> 0.05)。结论疏肝胃安颗粒联合埃索美拉唑镁肠溶片和莫沙必利片可以明显改善胃食管反流病患者的临床症状和生活质量,其临床疗效优于单纯西药治疗。Objective To evaluate the clinical efficacy of Shugan Weian Granules(疏肝胃安颗粒) combined with esomeprazole and mosapride in the treatment of gastroesophageal reflux disease(GERD).Methods Totally120 patients with GERD were randomly divided into a control group(60 cases) and a treatment group(60 cases).The control group was given esomeprazole magnesium enteric-coated tablets 20 mg each time,twice a day,and mosapride 5 mg each time,3 times a day.On the basis of the control group,the treatment group was given Shugan Weian Granules additionally,one dose per day.The treatment course of both group was 8 successive weeks.Before and after treatment,reflux disease questionnaire scale(RDQ),SF-36 quality of life scale,and 24-hour esophageal pH monitoring were observed respectively.After treatment,the curative effect of both groups was analyzed according to the changes of the electronic gastroscope grading score before and after treatment.Results After treatment,the symptom scores of acid reflux,reflux,heartburn and non-cardiogenic chest pain and the total score of RDQ were significantly decreased in both groups(P<0.01),while total score of RDQ and scores of all symptoms in the treatment group showed more significant decrease than those in the control group(P<0.05 or P<0.01).In SF-36 scale,all scores in the treatment group and scores except the emotional function and mental health in the control group were significantly increased than those before treatment(P<0.05).And the treatment group showed better improvement in physiological function,body pain,general health,emotional function,and mental health compared with the control group(P<0.05 or P<0.01).The number of reflux lasting ≥5 min,the longest reflux duration,time percentage of pH<4,De Meester scoring were significantly reduced in both groups(P<0.05 or P<0.01).Additionally,the longest reflux duration and DeMeester scoring showed more significant decrease in the treatment group compared with the control group(P<0.05).There was no significant difference in the tot

关 键 词：胃食管反流病 疏肝胃安颗粒 反流性疾病问卷 生活质量 

分 类 号：R571[医药卫生—消化系统]